Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus Low-Dose Dexamethasone in Chinese RRMM
NCT01593410Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2010
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Started Aug 2010; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01593410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01593410.